Lung Adenocarcinoma — Trials

Lung Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

231 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 27
Ph III recruiting: 6
Growth YoY: —
Industry share: 13%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (28)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07416058	PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC(PHOENIX)	not yet recruiting	Phase 2	61	Guangdong Association of Clinical TrialsOTHER	0	Feb 17, 2026	clinicaltrials
NCT06818955	Orlistat Overcoming Third-generation EGFR-TKI Resistance(OOTER)	not yet recruiting	Phase 2	36	Ping PengOTHER	0	Feb 12, 2025